Athersys (ATHX) stock forecast for 2022
Last update: September 23, 2023 (07:29)
Sector: HealthcareThe share price of Athersys, Inc. (ATHX) now
50/200 Day Moving Average: $0.528 / $0.954
This figure corresponds to the Average Price over the previous 50/200 days. For Athersys stocks, the 50-day moving average is the resistance level today.
For Athersys stocks, the 200-day moving average is the resistance level today.
Are you interested in Athersys stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Athersys stock price in 2022. How much will one Athersys share be worth in 2022? Is it worth taking profit / loss on Athersys stock now or waiting? What are analysts' forecasts for Athersys stock?
We forecast Athersys stock performance using neural networks based on historical data on Athersys stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. The Athersys stock prediction results are shown below and presented as a graph, table and text information.
Athersys stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Athersys analysts is $5.5.
Today 200 Day Moving Average is the resistance level (0.954 $).
50 Day Moving Average is the resistance level (0.528 $).
Historical and forecast chart of Athersys stock
The chart below shows the historical price of Athersys stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Athersys stock price can be found in the table below.
Athersys (ATHX) Forecast for 2022
| Month | Target | Pes. | Opt. | Vol., % |
|---|
Athersys information and performance
Athersys Inc. is an international biotech company focused primarily on the field of regenerative medicine. The Company’s Multistem Cell Therapy, an allogeneic stem cell product, is its flagship platform product and is in a later stage of clinical development. Its clinical development programs are focused on the treatment of neurological diseases, cardiovascular disease, inflammatory and immune disorders, certain lung diseases, and other conditions where the standard of care is limited or inadequate for many patients.
3201 CARNEGIE AVENUE, CLEVELAND, OH, US
Market capitalization of the Athersys, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ATHX shares in the company outstanding by the market price of one share.
EBITDA of Athersys is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.